Progress and regression within primary Sjögren's syndrome

References

• Manthorpe R., Manthorpe T. [Primary Sjögren's Syndrom – Epidemiology and Prognosis] German. Akt Rheumatol 2005; 30: 27–31
   Google Scholar
• Fox R. I. Sjögren's syndrome. Lancet 2005; 366: 321–31
   PubMed Web of Science ®Google Scholar
• Venables P. J. Sjögren's syndrome. Best Pract Res Clin Rheumatol 2004; 18: 313–29
   PubMedGoogle Scholar
• Proceedings of: 1st International Seminar on Sjögren's Syndrome 1986. Scand J Rheumatol Suppl 1986; 61: 1–291, Copenhagen, May, 1986
   PubMedGoogle Scholar
• Carlsson M. Henrik Sjögren – a medical historical presentation. Hygiea 1999; 108: 1–3
   Google Scholar
• Kok M. R. Use of localized gene transfer to develop novel treatment strategies for the salivary component of Sjögren's syndrome. 2005; 1–157, Thesis. University of Amsterdam
   Google Scholar
• The 100‐year anniversary of Henrik Sjögren, September 1999, Jönköping, Sweden. Hygiea 1999; 108: 1–114
   Google Scholar
• Vitali C., Bombardieri S., Moutsopoulos H. M., Balestrieri G., Bencivelli W., Bernstein R. M., et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340–7
   PubMed Web of Science ®Google Scholar
• Vitali C., Moutsopoulos H. M., Bombardieri S., the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994; 53: 637–47
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Moutsopoulos H. M., Coll J., Gerli R., the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996; 55: 116–21
   PubMed Web of Science ®Google Scholar
• Vivino F. B., Gala I., Hermann G. A. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 2002; 29: 938–44
   PubMedGoogle Scholar
• Sjögren H. [Knowlegde of Keratoconjunctivitis sicca] German. Acta Ophthalmol 1933; 11: 1–151
   Google Scholar
• Asmussen K., Andersen V., Bendixen G., Schiødt M., Oxholm P. A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long‐term study. Intern Med 1996; 239: 475–82
   Google Scholar
• Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carssons S. E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American–European consensus group. Ann Rheum Dis 2002; 61: 554–8
   PubMed Web of Science ®Google Scholar
• Daniels T. E. Labial salivary gland biopsy in Sjögren's syndrome: assessment on a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984; 27: 147–56
   PubMed Web of Science ®Google Scholar
• Manthorpe R., Benoni C., Jacobsson L., Kirtava Z., Larsson Å., Liedholm R., et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti‐SSA/Ro and anti‐SSB/La antibodies in Sjögren's syndrome?. Ann Rheum Dis 2000; 59: 54–60
   PubMed Web of Science ®Google Scholar
• Wiik A. S. Anti‐nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005; 34: 260–8
   PubMed Web of Science ®Google Scholar
• Segerberg‐Konttinen M. Focal sialadenitis in lacrimal and salivary glands. A post‐mortem study. Scand J Rheumatol 1985; 17: 379–85
   Google Scholar
• Radfar L., Kleiner D. E., Fox P. C., Pillemer S. R. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Care Res 2002; 47: 520–4
   Google Scholar
• Kassan S. S., Thomas T., Moutsopoulos H. M., Hoover R., Kimberly R. P., Budman D. R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888–92
   PubMed Web of Science ®Google Scholar
• Voulgarelis M., Dafni U., Isenberg D., Moutsopoulos H. M., Jonsson R., Haga H‐J., et al. Malignant lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1999; 42: 1765–72
   PubMed Web of Science ®Google Scholar
• Ioannidis J. P., Vassliou V. A., Moutsopoulos H. M. Long‐term risk of mortality and lymphoproliferative disease and predictive classification in primary Sjögren's syndrome. Arthritis Rheum 2002; 46: 741–7
   PubMed Web of Science ®Google Scholar
• Sutcliffe N. N., Inanc M., Speight P., Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998; 28: 80–7
   PubMed Web of Science ®Google Scholar
• Theander E. Living and dying with primary Sjögren's syndrome. Studies on aetiology, treatment, lymphoma, survival and predictors. 2005, Thesis. Lund University, Malmö
   Google Scholar
• Kirtava Z., Blomberg J., Bredberg A., Henriksson G., Jacobsson L., Manthorpe R. CD4+ T‐lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995; 13: 609–16
   PubMed Web of Science ®Google Scholar
• Mandl T., Bredberg A., Jacobsson L., Manthorpe R., Henriksson G. CD+ T‐lymphocytopenia – a frequent finding in anti‐SSA positive patients with primary Sjögren's syndrome. J Rheumatol 2004; 31: 726–8
   PubMed Web of Science ®Google Scholar
• Manthorpe R., Oxholm P., Prause J. U., Schiødt M. The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol 1986; Suppl 61: 19–21
   Google Scholar
• Isager H., Frost‐Larsen K., Manthorpe R. Remission in a patient with Sjögren's syndrome induced by bromhexine. Ugeskr Læger 1977; 139: 3003–4
   PubMedGoogle Scholar
• Frost‐Larsen K., Isager H., Manthorpe R. Sjögren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978; i: 1579–81
   Google Scholar
• Manthorpe R., Frost‐Larsen K., Isager H., Prause J. U. Lack of lacrimal gland improvement by NA‐872 in Sjögren's syndrome. Acta Ophthalmol 1981; 59: 428–9
   Google Scholar
• Vivino F. B., Al‐Hashimi I., Khan Z., LeVeque F. G., Salisbury P. L., Tran‐Johnson T. K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome. Arch Intern Med 1999; 159: 174–81
   PubMed Web of Science ®Google Scholar
• Oxholm P., Prause J. U., Schiødt M. Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. Drugs 1998; 56: 345–53
   PubMedGoogle Scholar
• Steinfeld S. D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001; 44: 2371–5
   PubMed Web of Science ®Google Scholar
• Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 1270–6
   PubMed Web of Science ®Google Scholar
• Sankar V., Brennan M. T., Kok M. R., Leakan R. A., Smith J. A., Manny J., et al. Etanercept in Sjögren's syndrome. A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trial. Arthritis Rheum 2004; 50: 2240–5
   PubMed Web of Science ®Google Scholar
• Eisenberg R. Update on rituximab. Ann Rheum Dis 2005; 64 Suppl 4: iv55–7
   PubMedGoogle Scholar
• Larsson Å., Bredberg A., Henriksson G., Manthorpe R., Sallmyr A. Immunohistochemistry of the B‐cell component in lower lip salivary glands of Sjögren's syndrome and healthy subjects. Scand J Immunol 2005; 61: 98–107
   PubMedGoogle Scholar
• Triantafyllopoulou A., Tapinos N., Moutsopoulos H. M. Evidence for coxsackievirus in primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 2897–902
   PubMedGoogle Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5
   PubMed Web of Science ®Google Scholar
• Bredberg A., Henriksson G., Larsson Å., Manthorpe R., Sallmyr A. Sjögren's syndrome and the danger model. Rheumatology 2005; 44: 965–70
   PubMedGoogle Scholar
• Bredberg A., Manthorpe R., Henriksson G. Recent findings shed light on the aethiopathogenesis of Sjögren's syndrome. Akt Rheumatol 2005; 30: 1–4
   Google Scholar
• Matzinger P. The danger model. Vox Sang 2004; 87(Suppl 2)18
   Google Scholar
• Moutsopoulos H. M. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994; 72: 162–5
   PubMedGoogle Scholar
• Tsubota K., Fujita H., Tsuzaka K., Takeuchi T. Mikulicz's disease and Sjogren's syndrome. Invest Ophthalmol Vis Sci 2000; 41: 1666–73
   PubMed Web of Science ®Google Scholar
• Yamamoto M., Ohara M., Suzuki C., Naishiro Y., Yamamoto H., Takahashi H., et al. Elevated IgG4 concentrations in serum of patients with Mikulicz's disease. Scand J Rheumatol 2004; 33: 432–3
   PubMed Web of Science ®Google Scholar
• Yamamoto M., Harada S., Ohara M., Suzuki C., Naishiro Y., Yamamoto H., et al. Clinical and pathological differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 227–34
   PubMed Web of Science ®Google Scholar